128 related articles for article (PubMed ID: 3675194)
1. Estrogen receptor protein of breast cancer in patients with positive nodes. High recurrence rates in the postmenopausal estrogen receptor-negative group.
Kinne DW; Butler JA; Kimmel M; Flehinger BJ; Menendez-Botet C; Schwartz M
Arch Surg; 1987 Nov; 122(11):1303-6. PubMed ID: 3675194
[TBL] [Abstract][Full Text] [Related]
2. Node-negative breast cancer treated by modified radical mastectomy without adjuvant therapies: variables associated with disease recurrence and survivorship.
Huseby RA; Ownby HE; Frederick J; Brooks S; Russo J; Brennan MJ
J Clin Oncol; 1988 Jan; 6(1):83-8. PubMed ID: 3335894
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients.
Crowe JP; Hubay CA; Pearson OH; Marshall JS; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; McGuire WL
Breast Cancer Res Treat; 1982; 2(2):171-6. PubMed ID: 7171837
[TBL] [Abstract][Full Text] [Related]
4. [The effect of axillary lymph node status on the prognosis of patients with local-regional recurrence after breast-conserving surgery].
Zhang Z; Zhang W; Li ZJ; Wang XM; Cao XC; Xiao CH
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):347-351. PubMed ID: 29860761
[No Abstract] [Full Text] [Related]
5. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
7. The correlation between estrogen receptor status, axillary-node metastases and disease-free interval after surgery in primary breast cancer.
Caldarola L; Calderini P; Volterrani P; Di Carlo F; Gaglia P
Ital J Surg Sci; 1983; 13(3):179-85. PubMed ID: 6643007
[TBL] [Abstract][Full Text] [Related]
8. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up.
Raemaekers JM; Beex LV; Koenders AJ; Pieters GF; Smals AG; Benraad TJ; Kloppenborg PW
Breast Cancer Res Treat; 1985; 6(2):123-30. PubMed ID: 4052639
[TBL] [Abstract][Full Text] [Related]
9. Nodal ratio of positive to excised nodes, but not number of positive lymph nodes is better to predict group to avoid chemotherapy among postmenopausal ER-positive, lymph node-positive T1-T2 breast cancer patients.
Jia XQ; Hong Q; Cheng JY; Li JW; Wang YJ; Mo M; Shao ZM; Shen ZZ; Liu GY
J Cancer Res Ther; 2015; 11(4):740-5. PubMed ID: 26881511
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptors and the pattern of relapse in breast cancer.
Qazi R; Chuang JL; Drobyski W
Arch Intern Med; 1984 Dec; 144(12):2365-7. PubMed ID: 6508445
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor protein of breast cancer as a predictor of recurrence.
Butler JA; Bretsky S; Menendez-Botet C; Kinne DW
Cancer; 1985 Mar; 55(6):1178-81. PubMed ID: 3971291
[TBL] [Abstract][Full Text] [Related]
12. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the pathologic and prognostic correlates of estrogen receptors in primary breast cancer.
Skinner JR; Wanebo HJ; Betsill WL; Wilhelm MC; Drake CR; Macleod RM
Ann Surg; 1982 Dec; 196(6):636-41. PubMed ID: 7149814
[TBL] [Abstract][Full Text] [Related]
14. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptors in primary breast cancer.
Neifeld JP; Lawrence W; Brown PW; Banks WL; Terz JJ
Arch Surg; 1982 Jun; 117(6):753-7. PubMed ID: 7082164
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor protein in breast cancer as a predictor of recurrence.
Kinne DW; Ashikari R; Butler A; Menendez-Botet C; Rosen PP; Schwartz M
Cancer; 1981 May; 47(10):2364-7. PubMed ID: 7272892
[TBL] [Abstract][Full Text] [Related]
17. Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma.
Tsangaris TN; Knox SM; Cheek JH
Cancer; 1992 Feb; 69(4):984-7. PubMed ID: 1735091
[TBL] [Abstract][Full Text] [Related]
18. Survival with breast cancer: the importance of estrogen receptor quantity.
Shek LL; Godolphin W
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):243-50. PubMed ID: 2702979
[TBL] [Abstract][Full Text] [Related]
19. Distribution of estrogen and progesterone receptors in primary tumor and lymph nodes in individual patients with breast cancer.
Coradini D; Cappelletti V; Miodini P; Ronchi E; Scavone G; Di Fronzo G
Tumori; 1984 Apr; 70(2):165-8. PubMed ID: 6730015
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor determination and long term survival of patients with carcinoma of the breast.
Crowe JP; Gordon NH; Hubay CA; Shenk RR; Zollinger RM; Brumberg DJ; McGuire WL; Shuck JM
Surg Gynecol Obstet; 1991 Oct; 173(4):273-8. PubMed ID: 1925896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
